Movatterモバイル変換


[0]ホーム

URL:


Jump to content
WikipediaThe Free Encyclopedia
Search

Glycopyrronium bromide

From Wikipedia, the free encyclopedia
Anticholinergic

Pharmaceutical compound
Glycopyrronium bromide
INN: Glycopyrronium
Clinical data
Trade namesRobinul, Cuvposa, Seebri, others
Other namesglycopyrrolate (USANUS)
AHFS/Drugs.comMonograph
MedlinePlusa602014
License data
Pregnancy
category
Routes of
administration
By mouth,intravenous,inhalation,topical,injection,subcutaneous
Drug classAntimuscarinic (peripherally-selective)
ATC code
Legal status
Legal status
Pharmacokinetic data
Eliminationhalf-life0.6–1.2 hours
Excretion85% Kidney, unknown amount in the bile
Identifiers
  • 3-[2-Cyclopentyl(hydroxy)phenylacetoxy]-1,1-dimethylpyrrolidinium bromide
CAS Number
PubChemCID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard(EPA)
ECHA InfoCard100.008.990Edit this at Wikidata
Chemical and physical data
FormulaC19H28BrNO3
Molar mass398.341 g·mol−1
3D model (JSmol)
  • C[N+]1(CCC(C1)OC(=O)C(C2CCCC2)(C3=CC=CC=C3)O)C.[Br-]

  • as cation: C[N+]1(CCC(C1)OC(=O)C(C2CCCC2)(C3=CC=CC=C3)O)C
  • InChI=1S/C19H28NO3.BrH/c1-20(2)13-12-17(14-20)23-18(21)19(22,16-10-6-7-11-16)15-8-4-3-5-9-15;/h3-5,8-9,16-17,22H,6-7,10-14H2,1-2H3;1H/q+1;/p-1
  • Key:VPNYRYCIDCJBOM-UHFFFAOYSA-M

  • as cation: InChI=1S/C19H28NO3/c1-20(2)13-12-17(14-20)23-18(21)19(22,16-10-6-7-11-16)15-8-4-3-5-9-15/h3-5,8-9,16-17,22H,6-7,10-14H2,1-2H3/q+1
  • Key:ANGKOCUUWGHLCE-UHFFFAOYSA-N
 ☒NcheckY (what is this?)  (verify)

Glycopyrronium bromide is amedication of themuscarinicanticholinergic group.[7] It does not cross theblood–brain barrier and consequently has few to no central effects. It is givenby mouth,[8] via intravenous injection,on the skin,[9] and viainhalation.[4][5][6] It is a syntheticquaternary ammonium compound.[2] Thecation, which is the activemoiety, is calledglycopyrronium (INN)[10] orglycopyrrolate (USAN).

The most common side effects includeirritability,flushing,nasal congestion, reduced secretions in the airways,dry mouth,constipation,diarrhea,nausea andvomiting, andurinary retention.[7]

In September 2012, glycopyrronium was approved for medical use in the European Union.[4] In June 2018, glycopyrronium was approved by the U.S.Food and Drug Administration (FDA) to treat excessive underarm sweating, becoming the first drug developed specifically to reduce excessive sweating.[11] It is on theWorld Health Organization's List of Essential Medicines.[12]

Medical uses

[edit]

Glycopyrronium was first used in 1961 to treatpeptic ulcers. Since 1975,intravenous glycopyrronium has been used before surgery to reducesalivary,tracheobronchial, andpharyngeal secretions.[13] It is also used in conjunction withneostigmine, aneuromuscular blocking reversal agent, to prevent neostigmine's muscarinic effects such asbradycardia.[14] It can be administered to raise theheart rate inreflex bradycardia as a result of avasovagal reaction, which often will also increase the blood pressure.[15]

It is also used to reduce excessive saliva (sialorrhea),[7][16][17][18] and to treatMénière's disease.[19]

It has been used topically and orally to treathyperhidrosis, in particular,gustatory hyperhidrosis andgeneralized hyperhidrosis.[20][21]

When inhaled, it is used to treatchronic obstructive pulmonary disease (COPD).[4][5][6] Doses for inhalation are much lower than oral ones, so that swallowing a dose will not have an effect.[22][23]

Side effects

[edit]

Dry mouth,urinary retention,headaches,vomiting,diarrhea,constipation, andblurry vision are possible side effects of the medication.[13]

Pharmacology

[edit]

Mechanism of action

[edit]

Glycopyrronium competitively blocksmuscarinic receptors,[13][24] thus inhibitingcholinergic transmission.

Pharmacokinetics

[edit]

Glycopyrronium bromide affects the gastrointestinal tracts, liver and kidney but has a very limited effect on the brain and thecentral nervous system. In horse studies, after a single intravenous infusion, the observed tendencies of glycopyrronium followed a tri-exponential equation, by rapid disappearance from the blood followed by a prolonged terminal phase. Excretion was mainly in urine and in the form of an unchanged drug. Glycopyrronium has a relatively slow diffusion rate, and in a standard comparison toatropine, is more resistant to penetration through the blood-brain barrier andplacenta.[25]

Research

[edit]

It has been studied inasthma.[26][27]

References

[edit]
  1. ^"Neurological therapies".Health Canada. 9 May 2018. Retrieved13 April 2024.
  2. ^ab"Robinul- glycopyrrolate tablet Robinul Forte- glycopyrrolate tablet".DailyMed. 1 June 2021. Retrieved20 June 2022.
  3. ^"Dartisla ODT- glycopyrrolate orally disintegrating tablets tablet, orally disintegrating".DailyMed. 9 December 2021. Retrieved20 June 2022.
  4. ^abcd"Seebri Breezhaler EPAR".European Medicines Agency (EMA). 17 September 2018.Archived from the original on 29 February 2020. Retrieved28 February 2020.
  5. ^abc"Tovanor Breezhaler EPAR".European Medicines Agency (EMA). 17 September 2018.Archived from the original on 29 February 2020. Retrieved28 February 2020.
  6. ^abc"Enurev Breezhaler EPAR".European Medicines Agency. 17 September 2018. Retrieved29 January 2023.
  7. ^abcd"Sialanar EPAR".European Medicines Agency. 17 September 2018. Retrieved29 January 2023. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
  8. ^"Glycopyrrolate Oral Inhalation".MedlinePlus.Archived from the original on 17 August 2021. Retrieved20 June 2022.
  9. ^"Glycopyrronium Topical".MedlinePlus.Archived from the original on 17 August 2021. Retrieved20 June 2022.
  10. ^Bajaj V, Langtry JA (July 2007). "Use of oral glycopyrronium bromide in hyperhidrosis".The British Journal of Dermatology.157 (1):118–121.doi:10.1111/j.1365-2133.2007.07884.x.PMID 17459043.S2CID 29080876.
  11. ^"FDA OKs first drug made to reduce excessive sweating".AP News.Archived from the original on 2018-07-02. Retrieved2018-07-02.
  12. ^World Health Organization (2021).World Health Organization model list of essential medicines: 22nd list (2021). Geneva: World Health Organization.hdl:10665/345533. WHO/MHP/HPS/EML/2021.02.
  13. ^abcChabicovsky M, Winkler S, Soeberdt M, Kilic A, Masur C, Abels C (May 2019). "Pharmacology, toxicology and clinical safety of glycopyrrolate".Toxicology and Applied Pharmacology.370:154–169.Bibcode:2019ToxAP.370..154C.doi:10.1016/j.taap.2019.03.016.PMID 30905688.S2CID 85498396.
  14. ^Howard J, Wigley J, Rosen G, D'mello J (February 2017). "Glycopyrrolate: It's time to review".Journal of Clinical Anesthesia.36:51–53.doi:10.1016/j.jclinane.2016.09.013.PMID 28183573.
  15. ^Gallanosa A, Stevens JB, Quick J (June 2023)."Glycopyrrolate".StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing.PMID 30252291. RetrievedSeptember 13, 2024.
  16. ^Mier RJ, Bachrach SJ, Lakin RC, Barker T, Childs J, Moran M (December 2000)."Treatment of sialorrhea with glycopyrrolate: A double-blind, dose-ranging study".Archives of Pediatrics & Adolescent Medicine.154 (12):1214–1218.doi:10.1001/archpedi.154.12.1214.PMID 11115305.Archived from the original on 2011-08-10. Retrieved2008-11-26.
  17. ^Tscheng DZ (November 2002). "Sialorrhea - therapeutic drug options".The Annals of Pharmacotherapy.36 (11):1785–1790.doi:10.1345/aph.1C019.PMID 12398577.S2CID 45799443.[permanent dead link]
  18. ^Olsen AK, Sjøgren P (October 1999)."Oral glycopyrrolate alleviates drooling in a patient with tongue cancer".Journal of Pain and Symptom Management.18 (4):300–302.doi:10.1016/S0885-3924(99)00080-9.PMID 10534970.
  19. ^Maria SA, Claudia C, Pamela G, Andrea C, Roberto A (1 December 2012). "Medical therapy in Ménière's disease".Audiological Medicine.10 (4):171–177.doi:10.3109/1651386X.2012.718413.S2CID 72380413.
  20. ^Kim WO, Kil HK, Yoon DM, Cho MJ (August 2003)."Treatment of compensatory gustatory hyperhidrosis with topical glycopyrrolate".Yonsei Medical Journal.44 (4):579–582.doi:10.3349/ymj.2003.44.4.579.PMID 12950111.
  21. ^Kim WO, Kil HK, Yoon KB, Yoon DM (May 2008). "Topical glycopyrrolate for patients with facial hyperhidrosis".The British Journal of Dermatology.158 (5):1094–1097.doi:10.1111/j.1365-2133.2008.08476.x.PMID 18294315.S2CID 39870296.
  22. ^"EPAR – Product information for Seebri Breezhaler"(PDF).European Medicines Agency. 28 September 2012.Archived(PDF) from the original on 30 July 2018. Retrieved4 February 2017.
  23. ^Tzelepis G, Komanapolli S, Tyler D, Vega D, Fulambarker A (January 1996)."Comparison of nebulized glycopyrrolate and metaproterenol in chronic obstructive pulmonary disease".The European Respiratory Journal.9 (1):100–103.doi:10.1183/09031936.96.09010100.PMID 8834341.
  24. ^Haddad EB, Patel H, Keeling JE, Yacoub MH, Barnes PJ, Belvisi MG (May 1999)."Pharmacological characterization of the muscarinic receptor antagonist, glycopyrrolate, in human and guinea-pig airways".British Journal of Pharmacology.127 (2):413–420.doi:10.1038/sj.bjp.0702573.PMC 1566042.PMID 10385241.
  25. ^Rumpler MJ, Colahan P, Sams RA (June 2014). "The pharmacokinetics of glycopyrrolate in Standardbred horses".Journal of Veterinary Pharmacology and Therapeutics.37 (3):260–268.doi:10.1111/jvp.12085.PMID 24325462.
  26. ^Hansel TT, Neighbour H, Erin EM, Tan AJ, Tennant RC, Maus JG, et al. (October 2005)."Glycopyrrolate causes prolonged bronchoprotection and bronchodilatation in patients with asthma".Chest.128 (4):1974–1979.doi:10.1378/chest.128.4.1974.PMID 16236844. Archived fromthe original on 2013-04-14.
  27. ^Gilman MJ, Meyer L, Carter J, Slovis C (November 1990)."Comparison of aerosolized glycopyrrolate and metaproterenol in acute asthma".Chest.98 (5):1095–1098.doi:10.1378/chest.98.5.1095.PMID 2225951. Archived fromthe original on 2013-04-14.
Drugs for
functional
bowel
disorders
Antimuscarinics
Tertiary
amino group
Quaternary
ammonium

compounds
Phosphodiesterase
inhibitors
Acting on
serotonin receptors
Other
Belladonna
and derivatives
(antimuscarinics)
Propulsives
Adrenergics,inhalants
Short-acting β2 agonists
Long-acting β2 agonists
Ultra-long-acting β2 agonists
Other
Glucocorticoids
Anticholinergics/
muscarinic antagonist
Mast cell stabilizers
Xanthines
Eicosanoid inhibition
Leukotriene antagonists
Arachidonate 5-lipoxygenase inhibitors
Thromboxane receptor antagonists
Non-xanthinePDE4 inhibitors
Others/unknown
Combination products
mAChRsTooltip Muscarinic acetylcholine receptors
Agonists
Antagonists
Precursors
(andprodrugs)
Portal:
Retrieved from "https://en.wikipedia.org/w/index.php?title=Glycopyrronium_bromide&oldid=1320510804"
Categories:
Hidden categories:

[8]ページ先頭

©2009-2025 Movatter.jp